Abbott, Teva Settle Patent Dispute Over TriCor, But Antitrust Claims Remain

Law360, New York (June 9, 2005, 12:00 AM EDT) -- Abbott Laboratories has settled a patent dispute with Israeli drug maker Teva Pharmaceutical Industries Ltd. over a generic version of Abbott's best-selling cholesterol treatment TriCor.

Abbott said the litigation had been amicably resolved and the parties have agreed to dismiss the patent claims, allowing Teva to go ahead with the launch of a generic TriCor.

However, Abbott said Teva's generic drug would be the equivalent of Abbott's older formulation of TriCor, not the newer formulation that Abbott has been marketing since getting Food and Drug Administration...
To view the full article, register now.